HeartBeam, Inc. (BEAT) - Q2 2025 10-Q Summary
Business Context and Reporting Period
HeartBeam, Inc. is a cardiac technology company developing ambulatory Electrocardiogram (ECG) solutions. The reporting period covers the quarter and six months ended June 30, 2025. The Company operates as a single segment focused on commercializing its proprietary 3D ECG technology platform. As of June 30, 2025, the Company had 19 employees and holds 21 issued patents worldwide.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | 6M 2025 | 6M 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(4,974) | $(4,956) | $(10,458) | $(9,562) |
| Operating Expenses | $5,037 | $5,090 | $10,538 | $9,874 |
| Cash & Short-Term Investments | $5,053 | $2,377 | $5,053 | $2,377 |
| Net Cash Used in Operating Activities (6M) | $(7,922) | $(7,013) | $(7,922) | $(7,013) |
| Net Cash Provided by Financing (6M) | $10,700 | $84 | $10,700 | $84 |
Note: Revenue is $0 as the Company expects no material commercial revenue in 2025. Cash and short-term investments total $5.1 million ($3.3M cash + $1.8M short-term investments).
Material Changes vs. Prior Period
- Capital Raise: In February 2025, the Company completed a public offering raising approximately $11.5 million in gross proceeds ($10.3 million net), significantly increasing liquidity compared to the prior year.
- Operating Expenses: Total operating expenses for the six months ended June 30, 2025, increased by 7% ($664k) compared to the same period in 2024. This was driven by a 29% increase in Research and Development (R&D) expenses due to product development and headcount growth, partially offset by a 19% decrease in General and Administrative (G&A) expenses.
- Stock-Based Compensation: Total stock-based compensation expense for the six months ended June 30, 2025, was $2.3 million, slightly higher than the $2.2 million recorded in the prior year period.
- Interest Income: Interest income decreased by 74% year-over-year for the six-month period, dropping from $312k to $80k, reflecting changes in cash deployment and investment yields.
Guidance, Outlook, and Risks
- Going Concern: Management has raised substantial doubt regarding the Company's ability to continue as a going concern. With a cash balance of $5.1 million and a current burn rate, existing liquidity is insufficient to fund operations for the next twelve months. Continued operations depend on raising additional capital.
- Regulatory Milestones: The Company received FDA clearance for its initial telehealth product (HeartBeam System) in December 2024. In January 2025, it filed a 510(k) for software algorithms to synthesize a 12-Lead ECG. The Company anticipates clearance for this software by December 31, 2025.
- Clinical Validation: In April 2025, the VALID-ECG pivotal study met its clinical endpoints, showing 93.4% diagnostic agreement with standard 12L ECGs for arrhythmia assessment.
- Strategic Partnerships: A collaboration with AccurKardia was announced to integrate automated ECG interpretation, aiming to reduce development costs and timelines.
- Financing Options: The Company has an At-the-Market (ATM) sales agreement with $15.6 million remaining available for issuance as of June 30, 2025.
Investor Verification Checklist
- Liquidity Runway: Verify the specific cash burn rate and the timeline for the next anticipated capital raise given the "substantial doubt" going concern warning.
- FDA Clearance Timeline: Confirm the status of the 510(k) submission for the 12L synthesis software and the probability of meeting the December 2025 clearance target.
- Commercialization Plan: Review the details of the "Early Access Program" and the timeline for generating material revenue post-clearance.
- Dilution Risk: Assess the impact of the recent public offering and potential future ATM sales on existing shareholders, noting the issuance of 6.7 million shares in February 2025.
- R&D Spend Efficiency: Monitor the increase in R&D expenses to ensure they are directly tied to the final stages of product development and regulatory approval.